证券代码：688553 证券简称：汇宇制药 公告编号：2025-025 四川汇宇制药股份有限公司 董事会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 四川汇宇制药股份有限公司（以下简称"公司""汇宇制药"）第二届董事会 第十四次会议于 2025 年 4 月 24 日以现场结合通讯表决方式在公司会议室召开。 会议通知和会议资料已于 2025 年 4 月 14 日以电子邮件方式发出。本次会议由董 事长丁兆先生主持，会议应出席董事 8 人，实际出席董事 8 人，相关监事及高管 列席。全体董事一致同意并认可本次会议的通知和召开时间、议案内容等事项， 本次董事会会议的召集和召开程序符合有关法律、行政法规、部门规章、规范性 文件和《公司章程》的规定，作出的决议合法、有效。 二、董事会会议审议情况 （一）审议通过《关于公司<2024 年度总经理工作报告>的议案》 同意《四川汇宇制药股份有限公司 2024 年度总经理工作报告》。 表决结果：8 票赞成；0 票弃权；0 票反对。 （二）审议通过《关于公司< ...

重要内容提示： 证券代码：688553 证券简称：汇宇制药 公告编号：2025-027 四川汇宇制药股份有限公司 2024 年度利润分配预案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 本次利润分配预案不会触及《上海证券交易所科创板股票上市规则 （2024 年 4 月修订）》（以下简称"《科创板股票上市规则》"）第 12.9.1 条 第一款第（八）项规定的可能被实施其他风险警示的情形。 一、利润分配预案内容 （一）利润分配预案的具体内容 经天健会计师事务所（特殊普通合伙）审计，公司 2024 年度合并报表中归 属于公司股东的净利润为 325,390,295.30 元。截至 2024 年 12 月 31 日，母公司 期末可供分配利润为人民币 1,096,539,207.89 元。经董事会决议，公司 2024 年度 拟以分红派息股权登记日的总股本扣减公司回购专用证券账户中的股份数为基 数进行分配利润，不转增股本，不送红股。本次利润分配预案如下： 拟向全体股东每 10 股派发现金红利 4.632 元（含税），截至 2025 ...

前十大流通股东累计持有： 12745.42万股，累计占流通股比： 41.17%，较上期变化： -17.45万 股。 | 持有数量(万股) 名称 | | 占总股本比例(%) | 增减情况(万股) | | --- | --- | --- | --- | | 黄乾益 | 2721.94 | 8.79 | 不变 | | 王晓鹏 | 1703.76 | 5.50 | 不变 | | 曹永明 | 1694.40 | 5.47 | 不变 | | 胡国平 | 1527.33 | 4.93 | 新进 | | 上海爽飒企业管理咨询事务所(有限合伙) | 1269.56 | 4.10 | 不变 | | 内江衡策企业管理咨询服务中心(有限合伙) | 1103.87 | 3.57 | 新进 | | 谭娟 | 773.57 | 2.50 | -31.09 | | 内江盛煜企业管理服务中心(有限合伙) | 735.91 | 2.38 | 新进 | | 易方达医疗保健行业混合A | 630.78 | 2.04 | -171.39 | | 吴水花 | 584.30 | 1.89 | -25.79 | | 较上个报告期退出前十大股东有 | | | ...

证券代码：688553 证券简称：汇宇制药 公告编号：2025-031 四川汇宇制药股份有限公司 关于作废处理 2023 年限制性股票激励计划已授予尚未归属 的限制性股票的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 2.2023 年 4 月 3 日，公司召开第一届监事会第十八次会议，审议通过《关于 公司<2023 年限制性股票激励计划（草案）>及其摘要的议案》《关于公司<2023 年限制性股票激励计划实施考核管理办法>的议案》《关于<公司 2023 年限制性 股票激励计划激励对象名单>的议案》。上述事项公司于 2023 年 4 月 6 日在上海 证券交易所网站（www.sse.com.cn）披露了相关公告。 3.2023 年 4 月 6 日，公司在上海证券交易所网站（www.sse.com.cn）披露了 《四川汇宇制药股份有限公司关于独立董事公开征集委托投票权的公告》。根据 公司其他独立董事的委托，独立董事龙永强作为征集人，就公司 2022 年年度股 东大会审议的本次激励计划相关议案向公司全体股东征集委托投票权。 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥239,052,524.64, a decrease of 1.46% compared to ¥242,604,188.27 in the same period last year[3]. - The net profit attributable to shareholders was -¥25,626,485.30, representing a decline of 155.19% from ¥46,435,905.16 year-on-year[3]. - Net profit for Q1 2025 was a loss of ¥26,685,549.35, compared to a profit of ¥44,879,334.61 in Q1 2024[15]. - The total comprehensive income for Q1 2025 was a loss of ¥27,288,527.71, compared to a profit of ¥44,948,732.88 in Q1 2024[16]. - The basic and diluted earnings per share were both -¥0.06, a decline of 154.55% from ¥0.11 in the same period last year[3]. - The company reported a basic and diluted earnings per share of -¥0.06 for Q1 2025, down from ¥0.11 in Q1 2024[16]. Cash Flow - The net cash flow from operating activities decreased by 80.94%, amounting to ¥2,561,923.01 compared to ¥13,438,049.99 in the previous year[3]. - The net cash flow from operating activities for Q1 2025 was ¥2,561,923.01, a significant decrease from ¥13,438,049.99 in Q1 2024[18]. - Cash flow from investing activities in Q1 2025 showed a net outflow of ¥187,495,816.08, compared to a net inflow of ¥39,578,048.79 in Q1 2024[19]. - Cash flow from financing activities resulted in a net outflow of ¥57,582,467.51 in Q1 2025, contrasting with a net inflow of ¥131,884,679.85 in Q1 2024[20]. Assets and Liabilities - Total assets at the end of the reporting period were ¥4,949,444,136.80, down 4.19% from ¥5,165,626,758.56 at the end of the previous year[4]. - The company's current assets totaled CNY 3,151,505,632.34, down from CNY 3,344,348,217.96, indicating a decrease of about 5.77%[11]. - Cash and cash equivalents decreased to CNY 1,981,653,478.45 from CNY 2,328,244,429.04, representing a decline of approximately 14.92%[11]. - The company's total liabilities were CNY 1,003,352,262.73, down from CNY 1,192,246,356.78, showing a reduction of about 15.85%[13]. - The total equity attributable to shareholders decreased to CNY 3,952,814,982.22 from CNY 3,979,044,445.88, reflecting a decline of approximately 0.66%[13]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 18,434[8]. - The largest shareholder, Ding Zhao, holds 26.93% of the shares, totaling 114,066,766 shares[8]. - Huang Qianyi, the second-largest shareholder, holds 6.43% of the shares, with 27,219,439 shares, of which 27,090,000 shares are pledged[8]. Research and Development - Research and development expenses totaled ¥67,083,832.82, accounting for 28.06% of operating revenue, an increase of 0.34 percentage points from the previous year[4]. - Research and development expenses for Q1 2025 were ¥61,856,632.31, a decrease of 5.0% from ¥65,507,169.10 in Q1 2024[15]. - The company's development expenditure increased to CNY 30,930,605.69 from CNY 25,703,405.18, representing an increase of approximately 20.00%[12]. Inventory and Accounts Payable - The company's inventory increased to CNY 202,748,808.40 from CNY 159,919,087.79, marking an increase of about 26.79%[11]. - The company's accounts payable decreased to CNY 145,309,958.59 from CNY 193,038,394.03, indicating a decline of approximately 24.69%[12]. Other Financial Metrics - The weighted average return on net assets was -0.65%, a decrease of 1.86 percentage points compared to 1.21% in the previous year[3]. - The company reported a decrease in retained earnings to CNY 927,980,229.38 from CNY 953,606,714.68, reflecting a decline of about 2.70%[13].

Financial Performance - The company achieved a net profit attributable to shareholders of RMB 325,390,295.30 for the year 2024, with a cumulative distributable profit of RMB 1,096,539,207.89 by the end of 2024[8]. - The proposed cash dividend is RMB 4.632 per 10 shares, totaling an estimated cash dividend of RMB 195,220,328.51, which accounts for 60.00% of the net profit attributable to shareholders for 2024[8]. - The company's operating revenue for 2024 reached ¥1,094,382,336.85, representing an 18.05% increase compared to ¥927,075,092.41 in 2023[40]. - Net profit attributable to shareholders for 2024 was ¥325,390,295.30, a significant increase of 132.78% from ¥139,785,741.88 in 2023[40]. - The net cash flow from operating activities for 2024 was ¥242,955,594.91, showing a remarkable increase of 262.98% compared to ¥66,932,697.85 in 2023[40]. - The company's total assets grew by 10.24% to ¥5,165,626,758.56 in 2024, up from ¥4,685,645,273.96 in 2023[40]. - Basic earnings per share for 2024 were ¥0.77, reflecting a 133.33% increase from ¥0.33 in 2023[41]. - The company's gross profit margin for 2024 was 83.36%, a decrease of 2.58 percentage points year-on-year[130]. - The company reported a significant increase in fair value gains of ¥239,856,212.20, up 3624.2% year-on-year[145]. - The total revenue for the company is 556,534.99 million RMB, with a net profit of 30,435.56 million RMB[115]. Shareholder Structure and Governance - The company has set up a special voting rights structure, with 80,466,766 A shares held by the actual controller, granting him five times the voting power of ordinary shares[14]. - The special voting rights mechanism allows the actual controller to have decisive influence over ordinary resolutions and significant decisions, potentially limiting the influence of other shareholders[16]. - The company has implemented measures to protect minority shareholders, including the right to convene extraordinary general meetings and propose agenda items[17]. - The company’s special voting rights structure is designed to remain in effect long-term, ensuring the actual controller's influence over corporate governance[11]. - As of December 31, 2024, the actual controller holds 53.97% of the total voting rights after the conversion of some A shares to B shares[14]. - The company’s board and supervisory board have confirmed the accuracy and completeness of the annual report, ensuring compliance with legal standards[4]. - The company will strictly adhere to the Shanghai Stock Exchange's regulations regarding special voting rights and will disclose relevant arrangements in periodic reports[22]. Research and Development - The company has 14 ongoing Class I innovative drug projects and 5 improved new drug projects, with an expectation of 2-3 innovative drugs entering clinical stages annually over the next three years[53]. - The company has launched 17 new drugs domestically, bringing the total number of launched drugs to 38, and has submitted 5 new drug registration applications, with 11 drugs pending approval[55]. - The company’s R&D expenditure as a percentage of operating revenue was 31.64% in 2024, down from 38.48% in 2023[41]. - The company has multiple products undergoing centralized procurement, which is expected to impact revenue positively[60]. - The company has evaluated over 100 projects for overseas licensing and late-stage innovative drug introductions, enhancing preparations for commercialization in China and overseas[67]. - The company has invested a total of $43 billion in biological innovative drugs, with $1.696 billion invested in the current period and a cumulative investment of $5.118 billion, aiming for new drug approval in China by 2025[106]. - The company has initiated clinical trials for several projects, with a focus on fast-follow strategies for drug development, targeting multiple types of solid tumors[107]. - The company has received approval for 101 overseas product registrations, with a total of over 400 approvals across 70 countries, contributing to over 100 million CNY in overseas sales revenue[63]. Market Expansion and Sales - The company is actively expanding its international business, covering 42 countries and regions across Asia, Oceania, North America, and Africa[58]. - The company is focusing on high-barrier, high-return generics while advancing the development of innovative drugs in oncology, including a dual-target small molecule drug and an antibody-drug conjugate[64]. - The company is expanding its market presence in the Asia-Pacific region, targeting a 20% increase in market share by 2025[177]. - The company is exploring partnerships for external authorization of its drug candidates, enhancing its market expansion strategy[107]. - The company has a strong pipeline of products with multiple approvals and ongoing registration reviews across various markets[199]. Risks and Challenges - The company faces risks related to price declines in products due to national procurement policies, which could significantly impact revenue stability in the coming years[5]. - The company faces risks related to drug procurement processes, including potential failure to win bids or price reductions[124]. - The company faces risks from potential changes in government subsidy policies that could adversely affect its operating performance[132]. - The normalization of volume-based procurement has led to a reduction in the lifecycle and profit margins of generic drugs, necessitating companies to have a diverse product line and cost control capabilities[88]. Product Development and Approvals - The company is preparing for the registration review of complex injectables, including paclitaxel albumin injection and leuprolide acetate sustained-release implant[190]. - The company has received approval for the injection of Azacitidine for the treatment of myelodysplastic syndromes and acute myeloid leukemia in Uzbekistan[199]. - The company is also in the registration review phase for the injectable formulation of Azacitidine, aimed at treating myelodysplastic syndromes and acute myeloid leukemia[196]. - The company has received approval for multiple injectable products, including 1,398.86 million for injectable teicoplanin, expected to be commercially produced by 2024[111]. - The company is actively pursuing collaborations for product approvals in international markets[199].

目 录 一、募集资金年度存放与使用情况鉴证报告………………………第 1—2 页 四川汇宇制药股份有限公司 募集资金年度存放与使用情况鉴证报告 + 二、关于募集资金年度存放与使用情况的专项报告…………… 第 3—13 页 三、附件……………………………………………………………第 14—17 页 （一）本所营业执照复印件………………………………………第 14 页 （二）本所执业证书复印件………………………………………第 15 页 （三）执业注册会计师资格证书复印件…………………… 第 16-17 页 募集资金年度存放与使用情况鉴证报告 天健审〔2025〕11-280 号 四川汇宇制药股份有限公司全体股东： 我们鉴证了后附的四川汇宇制药股份有限公司（以下简称汇宇制药公司）管 理层编制的 2024 年度《关于募集资金年度存放与使用情况的专项报告》。 一、对报告使用者和使用目的的限定 本鉴证报告仅供汇宇制药公司年度报告披露时使用，不得用作任何其他目的。 我们同意将本鉴证报告作为汇宇制药公司年度报告的必备文件，随同其他文件一 起报送并对外披露。 二、管理层的责任 汇宇制药公司管理层的责任是提供真实、合法、完整的相关资料， ...

四川汇宇制药股份有限公司 内部控制审计报告 + 目 录 | 一、内部控制审计报告………………………………………… | 第 | 1—2 | 页 | | --- | --- | --- | --- | | 二、附件………………………………………………………… | 第 | 3—6 | 页 | | （一）本所营业执照复印件…………………………………………第 | | 3 | 页 | | （二）本所执业证书复印件…………………………………………第 | | 4 | 页 | | （三）执业注册会计师资格证书复印件…………………………第 | | 5-6 | 页 | 内部控制审计报告 天健审〔2025〕11-278 号 四川汇宇制药股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我 们审计了四川汇宇制药股份有限公司（以下简称汇宇制药公司）2024 年 12 月 31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》《企业内部控制应用指引》以及《企业内部 控制评价指引》的规定，建立健全和有效实施内部控制，并评价其有效性是汇宇 制药公司董事会的责任。 二、 ...

中信建投证券股份有限公司 关于四川汇宇制药股份有限公司 2024年度募集资金存放与实际使用情况的专项核查意见 中信建投证券股份有限公司（以下简称"中信建投证券""保荐机构"）作 为四川汇宇制药股份有限公司(以下简称"汇宇制药"或"公司")首次公开发行 股票并在科创板上市的保荐机构，根据《证券发行上市保荐业务管理办法》《上 市公司监管指引第2号——上市公司募集资金管理和使用的监管要求》《上海证 券交易所科创板上市公司自律监管指引第1号——规范运作》等有关规定，就汇 宇制药截至2024年12月31日募集资金存放与实际使用情况进行了审慎核查，并出 具核查意见如下： 一、募集资金基本情况 （一）实际募集资金金额和资金到账时间 经中国证券监督管理委员会《关于同意四川汇宇制药股份有限公司首次公开 发行股票注册的批复》（证监许可〔2021〕2596号）核准，并经上海证券交易所 同意，公司由主承销商中信建投证券股份有限公司采用余额包销方式，向社会公 众公开发行人民币普通股（A股）股票63,600,000股，发行价为每股人民币38.87 元，共计募集资金2,472,132,000.00元，扣除承销和保荐费用（不含增值税） 98 ...

上海东方华银律师事务所 法律意见书 上海市虹桥路 1591 号虹桥迎宾馆 34 号楼 电话：(8621) 6876 9686 传真：(8621) 5830 4009 上海东方华银律师事务所 关于四川汇宇制药股份有限公司 作废处理 2023 年限制性股票激励计划 已授予尚未归属的限制性股票 关于四川汇宇制药股份有限公司 作废处理 2023 年限制性股票激励计划 已授予尚未归属的限制性股票 之 1、2023 年 4 月 3 日，公司召开第一届董事会第二十七次会议，审议通过《关于 公司<2023 年限制性股票激励计划（草案）>及其摘要的议案》《关于公司<2023 年 限制性股票激励计划实施考核管理办法>的议案》《关于提请股东大会授权董事会办 理 2023 年限制性股票激励计划相关事宜的议案》，公司独立董事对本激励计划及相 关议案发表了明确同意的独立意见。 2、2023 年 4 月 3 日，公司召开第一届监事会第十八次会议，审议通过《关于公 司<2023 年限制性股票激励计划（草案）>及其摘要的议案》《关于公司<2023 年限 制性股票激励计划实施考核管理办法>的议案》《关于<公司 2023 年限制性股票激励 计划激 ...